Skip to main content

Table 1 Patient demographics

From: Incidence of subsequent primary cancers and radiation-induced subsequent primary cancers after low dose-rate brachytherapy monotherapy for prostate cancer in long-term follow-up

 n (%)
All patients241 (100)
Age (y)
 Median65
 Range46–79
T classification at diagnosis
 T1148 (61.4)
 T2a75 (31.1)
 T2b9 (3.7)
 T2c-39 (3.7)
Gleason score at diagnosis
 ≤ 6208 (86.3)
 726 (10.8)
 ≥ 82 (0.8)
 NA5 (2.1)
PSA at diagnosis (ng/ml)
 PSA ≤ 10165 (68.5)
 PSA 10.1–19.971 (29.5)
 PSA ≥ 205 (2.1)
D’Amico risk group
 Low142 (58.9)
 Intermediate85 (35.3)
 High14 (5.8)
Short term ADT
 No188 (78.0)
 Yes53 (22.0)
  1. PSA Prostate-specific antigen, ADT Androgen deprivation therapy, NA Not available